Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers
Join us for the March CDx Insights webinar “Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive Biomarkers.” Our speaker is Yaso Natkunam, MD, PhD, Professor of Pathology and Director of Hematopathology at Stanford University School of Medicine. Dr Natkunam will review key updates to the classifications of large B-cell lymphomas in the “2016 revision of the World Health Organization classification of lymphoid neoplasms.” She will also discuss the role of diagnostic and predictive biomarkers in DLBCL, high grade B-cell lymphoma and other large B-cell lymphomas.
RecordedMar 29 201758 mins
Your place is confirmed, we'll send you email reminders
Dr. Sonja Klebe of SA Pathology and Flinders University, Australia, will share data from two recently published studies investigating immunohistochemistry using various TTF-1 clones for diagnosis of lung cancer and metastases of other origins. She will discuss the sensitivity and specificity of the different TTF-1 clones and the resulting implications in identifying lung, prostate, and colorectal adenocarcinomas.
The Lopez-Rios lab and their colleagues throughout Spain have published a very informative study (The ROSING Study) on ROS1 in Journal of Thoracic Oncology. Dr. Fernando Lopez-Rios will be presenting the data from the manuscript and be available for questions following his live presentation.
In this webinar, Dr. Konnick will discuss the biology, background and
rationale for targeting TRK fusions. You will learn about the clinical
evidence for TRK inhibitors and issues implementing pan-tumor assays,
specifically pan-TRK assays.
Panel Discussion-Prioritizing Testing in the Context of Predictive Markers hosted by Dr. Paul A. Bunn Jr, MD. Panel participants include Dr. Philippe Taniere, MD, PhD, Dr. Erik Thunnissen, FBJM, and Dr Emd (Ed) Schuuring, Prof Dr.
Panel Discussion-Making Appropriate Diagnosis in Lung Cancer with Dr. Paul A. Bunn Jr, MD,as your host. The panel includes Dr. Corrado D'Arrigo, MBChB, PhD, FRCPath, Dr. Mark Kockx, MD, PhD, and Dr. Erik Thunnissen, FBJM.
Panel Discussion-Collaboration and Partnership between Oncologists and Pathologists with Dr. Paul A. Bunn, MD, as your host. Panel participants include Prof Dr. EMD (Ed) Schuuring, Prof Dr. HJM (Harry) Groen, and Dr. Corrado D'Arrigo, MBChB, PhD, FRCPath
The Dangers of Using a Laboratory-Developed Test as a Companion Diagnostic presented by Keith Miller, FIBMS, Director, UK National External Quality Assessment Scheme for Immunohistochemistry and in Situ Hybridization
Prof Dr EMD (Ed) Schuuring and Prof Dr HJM (Harry) Groen
ALK IHC vs ISH and ALK Inhibitors in Treatment of ALK-Positive Advanced NSCLC presented by Prof Dr. EMD (Ed) Schuuring, Clinical Scientist in Molecular Pathology, University Medical Center Groningen The Netherlands and Prof Dr. HJM (Harry) Groen, Pulmonologist, University Medical Center Groningen The Netherlands.
Prof Dr EMD (Ed) Schuuring & Prof Dr HJM (Harry) Groen
Join Dr. Ed Schuuring and Dr. Harry Groen, University Medical Center Groningen, The Netherlands, to explore the role of immunohistochemistry (IHC) in the assessment of ALK rearrangements in non-small cell lung cancer (NSCLC), with a focus on the binary algorithm and comparison with fluorescence in situ hybridization (FISH). Clinical implications for ALK IHC vs. FISH and treatment options for ALK inhibitors will be discussed including side effects and overall as well as intracranial efficacy.
In this webinar, Dr. Flores will summarize the PD-L1 testing assays currently available on market and address the importance of understanding the different scoring algorithms developed for their respective PD-1/PD-L1 immunotherapies. You will learn about a system approach to testing and where to find further information on how to appropriately interpret the specific PD-L1 assay you are working with.
There is an ever increasing need to understand the role of the Tumor Microenvironment (TME) in Cancer Immunotherapy. In this webinar, Drs. Lei Tang, PhD and Mehrnoush Khojasteh,PhD of Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), present their work on multiplex immunofluorescence staining and digital pathology analysis in a CAP/CLIA certified laboratory. Multiplexed immunohistochemistry (IHC) enables the spatial characterization of TME immune cells and tumor cells by detecting multiple biomarkers while preserving tissue morphology. Co-expression of multiple biomarkers and relative spatial relationships requires whole slide digital pathology image analysis algorithms that are tailored to individual assays and their intended uses. The process described in this presentation demonstrates how multiplexing and digital pathology enable biotech and pharmaceutical research and development teams to explore the potential medical value of specific biomarkers,
Professor Keith Kerr, MB, ChB, FRCPath, FRCPE, Consultant Pathologist, Department of Pathology, University of Aberdeen, Aberd
Immunotherapy is changing the cancer care paradigm: for a small but significant group of patients, cancer has become a chronic disease and immunotherapy biomarkers like PD-L1 play an important role. In this presentation, Professor Kerr will provide a summary of the immunotherapy treatment landscape, address what makes immunotherapy biomarkers unique compared to biomarkers like HER-2 and ALK, describe the function (physiologic and as a biomarker) of PD-L1 and other biomarkers relevant to the PD-1/PD-L1 pathway. He will also address the role of emerging immunotherapy biomarkers that are independent of the PD-1/PD-L1 pathway.
CDx Insights is a series brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
Large B-Cell Lymphomas: WHO 2016 Classification Update and Predictive BiomarkersYaso Natkunam, MD, PhD, Professor of Pathology, Director of Hematopathology, Stanford University School of Medicine[[ webcastStartDate * 1000 | amDateFormat: 'MMM D YYYY h:mm a' ]]58 mins